BIOCRYST PHARMACEUTICALS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 on October 15, 2026. There are 3 upcoming events on record.
Cash runway is approximately 17.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 50 concluded trials, 74% reached completion rather than being terminated or withdrawn.
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.